Faron Pharmaceuticals Limited (AIM:FARN) has issued 352,989 new shares following the exercise of special rights linked to its €15 million convertible bond agreement with Heights Capital Management. The shares, priced at €2.5709 each, settle a €907,500 amortisation and interest payment under the bond’s first tranche. The new shares will be admitted to trading on AIM and Nasdaq First North on or around 4 June 2025
Advertisement Go to Proactive UK Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Advertisement Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Advertisement Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com